지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 616 - 629 (14page)
이용수
초록· 키워드
오류제보하기
Purpose This subgroup analysis of a phase II trial was conducted to assess possible ethnicity-basedtrends in efficacy and safety in East Asian (EA) and non-EA populations with nonsquamousnon-small cell lung cancer (NSCLC).
Materials and MethodsNever-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLCincluded 133 EA patients randomized to pemetrexed supplemented with dexamethasone,folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), orpemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37),erlotinib (n=33), or pemetrexed (n=37). The primary endpoint, progression-free survival(PFS), was analyzed using a multivariate Cox model.
ResultsConsistent with the results of the overall study, a statistically significant difference in PFSamong the three arms was noted in the EA population favoring pemetrexed-erlotinib (overallp=0.003) as compared with either single-agent arm (hazard ratio [HR], 0.48; 95%confidence interval [CI], 0.29 to 0.79; p=0.004 vs. erlotinib; HR, 0.40; 95% CI, 0.23 to 0.70;p=0.001 vs. pemetrexed). The EA patients treated with pemetrexed-erlotinib achieved alonger median PFS (7.4 months) compared with erlotinib (4.5 months) and pemetrexed(4.0 months). The PFS results also numerically favored pemetrexed-erlotinib in the non-EApopulation (overall p=0.210) (HR, 0.62; 95% CI, 0.37 to 1.05; p=0.078 vs. erlotinib; HR,0.75; 95% CI, 0.42 to 1.32; p=0.320 vs. pemetrexed) (median PFS: pemetrexed-erlotinib,6.7 months; erlotinib, 3.0 months; pemetrexed, 4.4 months).
ConclusionThe PFS results from this subset analysis in both EA and non-EA populations are consistentwith the results in the overall population. The PFS advantage for pemetrexed-erlotinib issignificant compared with the single agents in EA patients.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Wu YL / 2013 / Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer(FASTACT-2) : a randomised, double-blind trial / Lancet Oncol 14:777~786
Brugger W / 2011 / Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer / J Clin Oncol 29:4113~4120
Gahr S / 2013 / EGFR mutational status in a large series of Caucasian European NSCLC patients : data from daily practice / Br J Cancer 109:1821~1828
Han JY / 2012 / First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung / J Clin Oncol 30:1122~1128
Bezjak A / 2006 / Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Grou
Brugger W / 2011 / Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer / J Clin Oncol 29:4113~4120
Gahr S / 2013 / EGFR mutational status in a large series of Caucasian European NSCLC patients : data from daily practice / Br J Cancer 109:1821~1828
Han JY / 2012 / First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung / J Clin Oncol 30:1122~1128
Bezjak A / 2006 / Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Grou
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pemetrexed in Treating Patients with Metastatic Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Pemetrexed Induces G1 Phase Arrest and Apoptosis through Inhibiting Akt Activation in Human Non Small Lung Cancer Cell Line A549
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
-
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
Cancer Research and Treatment
2015 .01
-
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer
Cancer Research and Treatment
2021 .01
-
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Cancer Research and Treatment
2019 .01
-
Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
Tuberculosis and Respiratory Diseases
2018 .01
-
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Cancer Research and Treatment
2022 .04
-
Original Article:The Continuation of Erlotinib Treatment in Non-Small Cell Lung Cancer Patients Whose Brain Lesion Is the Only Site of Progression: Prospective Pilot Study
Hanyang Medical Reviews
2015 .01
-
Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
Yonsei Medical Journal
2021 .01
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Yonsei Medical Journal
2018 .01
-
Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Gefitinib 내성 후 Erlotinb과 한방 치료를 병행하여 호전된 뇌전이를 동반한 재발성 L858R 변이 비소세포폐암 환자 1례
대한한방내과학회지
2022 .10
-
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Cancer Research and Treatment
2019 .01
-
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
Yonsei Medical Journal
2016 .01
-
A Case of Pneumatosis Cystoides Intestinalis after Erlotinib-containing Chemotherapy for Pancreatic Cancer
대한췌담도학회지
2016 .01
-
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Cancer Research and Treatment
2015 .01
-
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Cancer Research and Treatment
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0